Welcome to our dedicated page for RAPT Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on RAPT Therapeutics stock.
RAPT Therapeutics, Inc. (NASDAQ: RAPT) is a clinical-stage biopharmaceutical company specializing in immunology-based treatments. Focused on developing and commercializing oral small molecule therapies, RAPT Therapeutics aims to address significant unmet medical needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company creates highly selective small molecules designed to modulate critical immune drivers underlying these conditions.
RAPT Therapeutics has two main drug candidates: FLX475 (tivumecirnon) and RPT193 (zelnecirnon). FLX475 targets the C-C motif chemokine receptor 4 (CCR4) and is designed to inhibit the migration of regulatory T cells into tumors, enhancing the immune response against cancer. RPT193, also targeting CCR4, focuses on inhibiting type 2 T helper cells in inflamed tissues, offering potential relief for inflammatory diseases like atopic dermatitis and asthma.
In recent developments, RAPT Therapeutics reported promising Phase 2 data for FLX475 in combination with pembrolizumab for non-small cell lung cancer (NSCLC) patients. The company also emphasized FLX475's potential in other cancers, including head and neck cancer, gastric cancer, and non-Hodgkin lymphoma. Despite a clinical hold placed by the FDA on the Phase 2 trials for zelnecirnon due to a serious adverse event, RAPT continues to investigate and aims to resolve the issue.
Financially, RAPT Therapeutics maintains a strong cash position, reporting $158.9 million in cash and equivalents by the end of 2023. The company is diligently working to advance its clinical programs and explore additional targets in the discovery stage, ensuring a robust pipeline for future developments.
RAPT Therapeutics has completed enrollment in its Phase 1b clinical trial of RPT193 for moderate to severe atopic dermatitis, with results expected by mid-2021. The trial aims to establish safety and clinical efficacy through multiple endpoints, including the Eczema Area and Severity Index and pruritis scale. An encouraging outcome may position RPT193 as a viable oral treatment option against existing injectable therapies, targeting significant unmet needs in inflammatory diseases.
RAPT Therapeutics (Nasdaq: RAPT) announced its financial results for Q4 and the year ending December 31, 2020. The company reported a net loss of $12.7 million for Q4 2020, slightly better than the $13.2 million loss in Q4 2019. Annual net loss increased to $52.9 million from $43 million in 2019. Research and development expenses rose to $45.5 million in 2020, driven by clinical trial costs for FLX475 and RPT193. As of December 31, 2020, cash and equivalents totaled $111.5 million. Key clinical advancements were noted for both lead programs, with upcoming data readouts expected in 2021.
RAPT Therapeutics (RAPT) reported promising data from preclinical studies to be presented at the American Association for Cancer Research annual meeting. Key findings include the ability of CCR4 antagonists to enhance CAR T-cell therapy's efficacy in solid tumors, with a significant increase in survival rates in murine models. Additionally, small-molecule HPK1 inhibitors demonstrated enhanced T-cell responses, while GCN2 inhibitors showed potential to restore immunity in the tumor microenvironment. These developments highlight RAPT's ongoing commitment to advancing immunology-based therapies for cancer treatment.
SOUTH SAN FRANCISCO, Calif., March 3, 2021 - RAPT Therapeutics (Nasdaq: RAPT) announced CEO Brian Wong will speak at two investor conferences this month. The H.C. Wainwright Global Life Sciences Conference features a company presentation available on March 9 at 7:00 am ET. Wong will also participate in the 33rd Annual Roth Conference on March 15 at 2:00 pm ET, discussing novel immuno-oncology targets. RAPT specializes in oral small molecule therapies for oncology and inflammatory diseases, focusing on advanced drug candidates like FLX475 and RPT193.
RAPT Therapeutics announced that its CEO, Brian Wong, M.D., Ph.D., will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 12:00 PM ET. The company focuses on immunology-based therapies for oncology and inflammatory diseases.
RAPT is developing small molecule therapies, including FLX475 and RPT193, targeting C-C motif chemokine receptor 4 (CCR4). For more details, visit the company's website.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Brian Wong, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 3:40 PM Eastern Time. The company focuses on developing oral small molecule therapies for oncology and inflammatory diseases. RAPT has advanced drug candidates targeting C-C motif chemokine receptor 4 (CCR4) and is exploring additional targets in early development. For those interested, the presentation will be available live and archived on their website.
RAPT Therapeutics announced that its executives will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Nov. 23, 2020, at 10:00 a.m. ET. The chat will feature Brian Wong, M.D., Ph.D., President and CEO, and Rodney Young, CFO. A replay of the discussion will be available on RAPT’s website. The company focuses on developing oral small molecule therapies for oncology and inflammatory diseases, with notable drug candidates including FLX475 and RPT193, targeting critical immune mechanisms.
RAPT Therapeutics reported a net loss of $14.6 million for Q3 2020, an increase from $10 million in Q3 2019. Research and development expenses rose to $12.9 million due to higher costs for clinical trials of FLX475 and RPT193. In the first nine months of 2020, the net loss totaled $40.2 million, up from $29.8 million in 2019. The company is advancing clinical trials and expects initial data from FLX475 and RPT193 by mid-2021. Cash and cash equivalents stood at $122.8 million as of September 30, 2020.
RAPT Therapeutics (RAPT) announced promising initial results from its Phase 1/2 trial of FLX475, highlighting monotherapy activity and efficacy in combination with pembrolizumab. The trial includes multiple cancer types, with favorable safety data and biomarker support for FLX475’s mechanism. RAPT plans to advance three cancer indications—EBV+ lymphoma, nasopharyngeal cancer, and head and neck cancer—into Phase 2 expansions based on early efficacy data. The company continues patient enrollment and anticipates further updates in the upcoming year.
RAPT Therapeutics announced plans to present initial data from its Phase 1/2 clinical trial of FLX475 for multiple cancer indications on November 16, 2020. The conference call will occur at 8:30 a.m. ET, and a live webcast will be available on the company's website. RAPT focuses on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases. Their drug candidates target key immune drivers, including CCR4. This data release is expected to provide insights into the efficacy and potential market impact of FLX475.
FAQ
What is the current stock price of RAPT Therapeutics (RAPT)?
What is the market cap of RAPT Therapeutics (RAPT)?
What does RAPT Therapeutics do?
What are the main drug candidates of RAPT Therapeutics?
What recent achievements has RAPT Therapeutics made?
What financial condition is RAPT Therapeutics in?
What is FLX475?
What is RPT193?
What is the status of the Phase 2 trials for zelnecirnon?
What recent financial results has RAPT Therapeutics reported?
How is RAPT Therapeutics funded for its ongoing operations?
What are the primary focuses of RAPT Therapeutics' research?
